Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: Managing Diabetes & CVD: Is epigenetics a new way forward? held at ESC 2017 in Barcelona

Video navigation menu

Apabetalone has a wide range of effects across the continuum of the atherosclerotic disease process 00:23
Early human clinical trials suggest that benefits seen in preclinical studies translate to clinical benefit in statin-treated patients 02:50
Apabetalone seems to affect plaque towards a less vulnerable phenotype 04:41
Biomarker analysis in clinical trials with apabetalone reinforce observations in preclinical studies 07:22
Preliminary observations in CV events in apabetalone-treated patients 10:50

Educational information

The educational objectives of this symposium were to:

To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Faculty

Stephen Nicholls, MD is Deputy Director and Heart Health Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI). He is Professor of Cardiology at the University of Adelaide, Consultant Cardiologist at the Royal Adelaide Hospital and Principal Research Fellow of the National Health and Medical Research Council of Australia

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Prof Nicholls disclosed the following related to this presentation- Research support: AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience - Consulting and honoraria: AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim

Funding

This symposium was supported by an unrestricted educational grant provided by Resverlogix

View Biography, abstract and keyslides View other lectures of this symposium View Slides of this lecture

Online-CME

This is available as accredited online CME on coursepath for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.